Loading clinical trials...
Loading clinical trials...
Knowing that the vaccine antigen includes the ACE2 binding moiety (RBD), the hypothesis is that circulating vaccine antigen could reduce the enzymatic activity of ACE2, and thus increase circulating A...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Centre Hospitalier Universitaire de Nīmes
NCT06631287 · Long COVID, Sars-CoV-2 Infection, and more
NCT04327570 · Coronavirus Infections
NCT04262921 · Coronavirus Infections
NCT06999018 · COVID-19, Coronavirus Infections, and more
NCT05800158 · COVID-19, Coronavirus Infections
CHU de Nîmes, Hôpital Universitaire Caremeau
Nîmes, France
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions